Antiproliferative and Cytotoxic Properties of Propynoyl Betulin Derivatives against Human Ovarian Cancer Cells: In Vitro Studies

Due to the incidence of ovarian cancer (OC) and the limitations of available therapeutic strategies, it is necessary to search for novel therapeutic solutions. The aim of this study was to evaluate the cytotoxic effect of betulin 1 and its propynoyl derivatives 2–6 against ovarian cancer cells (SK-OV-3, OVCAR-3) and normal myofibroblasts (18Co). Paclitaxel was used as the reference compound. The propynoyl derivatives 2–6 exhibited stronger antiproliferative and cytotoxic activities compared to betulin 1. In both ovarian cancer cell lines, the most potent compound was 28-propynoylbetulin 2. In the case of compound 2, the calculated IC50 values were 0.2 µM for the SK-OV-3 cells and 0.19 µM for the OVCAR-3 cells. Under the same culture conditions, the calculated IC50 values for compound 6 were 0.26 µM and 0.59 µM, respectively. It was observed that cells treated with compounds 2 and 6 caused a decrease in the potential of the mitochondrial membrane and a significant change in cell morphology. Betulin 1, a diol from the group of pentacyclic triterpenes, has a confirmed wide spectrum of biological effects, including a significant anticancer effect. It is characterized by low bioavailability, which can be improved by introducing changes to its structure. The results showed that chemical modifications of betulin 1 only at position C-28 with the propynoyl group (compound 2) and additionally at position C-3 with the phosphate group (compound 3) or at C-29 with the phosphonate group (compound 6) allowed us to obtain compounds with greater cytotoxic activity than their parent compounds, which could be used to develop novel therapeutic systems effective in the treatment of ovarian cancer.

[1]  Shanshan Cheng,et al.  Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status , 2023, Journal of Ovarian Research.

[2]  Angela A Alexander-Bryant,et al.  Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets , 2022, Cancers.

[3]  I. McNeish,et al.  Risk Factors for Ovarian Cancer: An Umbrella Review of the Literature , 2022, Cancers.

[4]  Zhi‐Jie Zheng,et al.  Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study , 2022, Cancers.

[5]  S. Głuszek,et al.  The Influence of Betulin and Its Derivatives EB5 and ECH147 on the Antioxidant Status of Human Renal Proximal Tubule Epithelial Cells , 2022, International journal of molecular sciences.

[6]  F. Bray,et al.  The ever‐increasing importance of cancer as a leading cause of premature death worldwide , 2021, Cancer.

[7]  P. Souček,et al.  Non-Coding RNAs as Biomarkers of Tumor Progression and Metastatic Spread in Epithelial Ovarian Cancer , 2021, Cancers.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  J. Kusz,et al.  Molecular Structure, In Vitro Anticancer Study and Molecular Docking of New Phosphate Derivatives of Betulin , 2021, Molecules.

[10]  E. Chodurek,et al.  Anticancer Activity of the Acetylenic Derivative of Betulin Phosphate Involves Induction of Necrotic-Like Death in Breast Cancer Cells In Vitro , 2021, Molecules.

[11]  A. Kinghorn,et al.  Apoptosis Induced by (+)-Betulin Through NF-κB Inhibition in MDA-MB-231 Breast Cancer Cells , 2020, AntiCancer Research.

[12]  Jenifer R Prosperi,et al.  Mechanisms of Taxane Resistance , 2020, Cancers.

[13]  N. Naumova,et al.  Regulation of Cell Death by Mitochondrial Transport Systems of Calcium and Bcl-2 Proteins , 2020, Membranes.

[14]  S. Tendulkar,et al.  Chemoresistance in Ovarian Cancer: Prospects for New Drugs. , 2020, Anti-cancer agents in medicinal chemistry.

[15]  P. Chung.  Novel targets of pentacyclic triterpenoids in Staphylococcus aureus: A systematic review. , 2020, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[16]  P. Pinton,et al.  Physiopathology of the Permeability Transition Pore: Molecular Mechanisms in Human Pathology , 2020, Biomolecules.

[17]  Y. Drew,et al.  Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting , 2020, Cancers.

[18]  A. Pescatore,et al.  Life, death, and autophagy in cancer: NF-κB turns up everywhere , 2020, Cell Death & Disease.

[19]  W. Chiu,et al.  Chemoresistant ovarian cancer enhances its migration abilities by increasing store-operated Ca2+ entry-mediated turnover of focal adhesions , 2020, Journal of Biomedical Science.

[20]  M. Hall,et al.  Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study , 2019, International Journal of Gynecological Cancer.

[21]  B. Rueda,et al.  Understanding and Targeting Apoptotic Pathways in Ovarian Cancer , 2019, Cancers.

[22]  K. Krukiewicz,et al.  Novel polymeric derivatives of betulin with anticancer activity , 2019, RSC advances.

[23]  J. Kusz,et al.  New phosphate derivatives of betulin as anticancer agents: Synthesis, crystal structure, and molecular docking study. , 2019, Bioorganic chemistry.

[24]  J. Kurzepa,et al.  Betulin and betulinic acid: triterpenoids derivatives with a powerful biological potential , 2019, Phytochemistry Reviews.

[25]  M. C. Vos,et al.  Presence of gastro-intestinal symptoms in ovarian cancer patients during survivorship: a cross-sectional study from the PROFILES registry , 2018, Supportive Care in Cancer.

[26]  Amareshwar T. K. Singh,et al.  Apoptosis: A Target for Anticancer Therapy , 2018, International journal of molecular sciences.

[27]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[28]  R. Oehler,et al.  The immune response to secondary necrotic cells , 2017, Apoptosis.

[29]  D. Green.  Cancer and Apoptosis: Who Is Built to Last? , 2017, Cancer cell.

[30]  E. Chodurek,et al.  Influence of 28-O-propynoylbetulin on proliferation and apoptosis of melanotic and amelanotic human melanoma cells. , 2016, Postepy higieny i medycyny doswiadczalnej.

[31]  A. Wiemer,et al.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier. , 2016, Topics in current chemistry.

[32]  M. Latocha,et al.  Betulin Phosphonates; Synthesis, Structure, and Cytotoxic Activity , 2016, Molecules.

[33]  X. Ji,et al.  Necrotic pyknosis is a morphologically and biochemically distinct event from apoptotic pyknosis , 2016, Journal of Cell Science.

[34]  G. Gordon,et al.  Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. , 2016, The Lancet. Oncology.

[35]  Angela C. M. Luyf,et al.  Betulinic acid induces a novel cell death pathway that depends on cardiolipin modification , 2016, Oncogene.

[36]  V. Velculescu,et al.  Beyond genomics: critical evaluation of cell line utility for ovarian cancer research. , 2015, Gynecologic oncology.

[37]  R. Advani,et al.  Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies , 2015, British journal of haematology.

[38]  V. Yuste,et al.  An Early and Robust Activation of Caspases Heads Cells for a Regulated Form of Necrotic-like Cell Death* , 2015, The Journal of Biological Chemistry.

[39]  Carmela Fimognari,et al.  Broad targeting of resistance to apoptosis in cancer , 2015, Seminars in cancer biology.

[40]  M. Kiełbus,et al.  Comprehensive Review on Betulin as a Potent Anticancer Agent , 2015, BioMed research international.

[41]  R. Schinazi,et al.  Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs , 2014, Chemical reviews.

[42]  E. Chodurek,et al.  Influence of betulin and 28-O-propynoylbetulin on proliferation and apoptosis of human melanoma cells (G-361). , 2014, Postepy higieny i medycyny doswiadczalnej.

[43]  J. Kusz,et al.  Synthesis, Structure and Cytotoxic Activity of New Acetylenic Derivatives of Betulin , 2013, Molecules.

[44]  Wiem Chaabane,et al.  Autophagy, Apoptosis, Mitoptosis and Necrosis: Interdependence Between Those Pathways and Effects on Cancer , 2012, Archivum Immunologiae et Therapiae Experimentalis.

[45]  U. Alon,et al.  Phosphate homeostasis and its role in bone health , 2012, Pediatric Nephrology.

[46]  Ying-hua Jin,et al.  Betulin induces mitochondrial cytochrome c release associated apoptosis in human cancer cells , 2010, Molecular carcinogenesis.

[47]  Osamu Hori,et al.  Cellular Stress Responses: Cell Survival and Cell Death , 2010, International journal of cell biology.

[48]  Zheng Zhou,et al.  Cellular and nuclear degradation during apoptosis. , 2009, Current opinion in cell biology.

[49]  J. Medema,et al.  Betulin Is a Potent Anti-Tumor Agent that Is Enhanced by Cholesterol , 2009, PloS one.

[50]  S. Fulda.  Tumor resistance to apoptosis , 2009, International journal of cancer.

[51]  J. Medema,et al.  Betulinic acid induces cytochrome c release and apoptosis in a Bax/Bak-independent, permeability transition pore dependent fashion , 2009, Apoptosis.

[52]  M. Dewhirst,et al.  A unique role of the DNA fragmentation factor in maintaining genomic stability , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[53]  S. Fulda,et al.  Sensitization for anticancer drug-induced apoptosis by betulinic Acid. , 2005, Neoplasia.

[54]  C. Zeiss,et al.  The Apoptosis-Necrosis Continuum: Insights from Genetically Altered Mice , 2003, Veterinary pathology.

[55]  W. Van den Broeck,et al.  Morphological and Biochemical Aspects of Apoptosis, Oncosis and Necrosis , 2002, Anatomia, histologia, embryologia.

[56]  Y. Kok,et al.  Necrosis has orderly DNA fragmentations. , 2002, Biochemical and biophysical research communications.

[57]  A. Melcher,et al.  Apoptosis or necrosis for tumor immunotherapy: what's in a name? , 1999, Journal of Molecular Medicine.

[58]  I. Jeremias,et al.  Betulinic acid: A new cytotoxic agent against malignant brain‐tumor cells , 1999, International journal of cancer.

[59]  M. Peter,et al.  Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. , 1997, Cancer research.

[60]  J. Weinberg,et al.  Internucleosomal DNA cleavage triggered by plasma membrane damage during necrotic cell death. Involvement of serine but not cysteine proteases. , 1997, The American journal of pathology.

[61]  P. Nicotera,et al.  Intracellular Adenosine Triphosphate (ATP) Concentration: A Switch in the Decision Between Apoptosis and Necrosis , 1997, The Journal of experimental medicine.

[62]  S. Głuszek,et al.  Betulin: a natural product with promising anticancer activityagainst colorectal cancer cells , 2020 .

[63]  Hamid Behrouj,et al.  Betulin and its derivatives as novel compounds with different pharmacological effects. , 2019, Biotechnology advances.